[{"address1": "3000 Pegasus Park Drive", "address2": "Suite 1430", "city": "Dallas", "state": "TX", "zip": "75247", "country": "United States", "phone": "214 612 0000", "website": "https://www.tayshagtx.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.", "fullTimeEmployees": 52, "maxAge": 86400, "priceHint": 4, "previousClose": 2.76, "open": 2.91, "dayLow": 2.745, "dayHigh": 2.99, "regularMarketPreviousClose": 2.76, "regularMarketOpen": 2.91, "regularMarketDayLow": 2.745, "regularMarketDayHigh": 2.99, "beta": 0.472, "forwardPE": -6.2978725, "volume": 5482231, "regularMarketVolume": 5482231, "averageVolume": 2219774, "averageVolume10days": 3496900, "averageDailyVolume10Day": 3496900, "bid": 2.92, "ask": 2.97, "bidSize": 400, "askSize": 600, "marketCap": 553573312, "fiftyTwoWeekLow": 0.5, "fiftyTwoWeekHigh": 4.32, "priceToSalesTrailing12Months": 39.105206, "fiftyDayAverage": 2.9867, "twoHundredDayAverage": 2.410275, "currency": "USD", "enterpriseValue": 490977088, "floatShares": 105874786, "sharesOutstanding": 187018000, "sharesShort": 17042982, "sharesShortPriorMonth": 16067454, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0911, "heldPercentInsiders": 0.18545, "heldPercentInstitutions": 0.75202006, "shortRatio": 10.61, "shortPercentOfFloat": 0.1241, "bookValue": 0.288, "priceToBook": 10.277779, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -118005000, "trailingEps": -0.78, "forwardEps": -0.47, "enterpriseToRevenue": 34.683, "enterpriseToEbitda": -6.312, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "TSHA", "underlyingSymbol": "TSHA", "shortName": "Taysha Gene Therapies, Inc.", "longName": "Taysha Gene Therapies, Inc.", "firstTradeDateEpochUtc": 1600954200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "fa02d192-bc05-33bd-8c2b-2973d0bcc5d6", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.96, "targetHighPrice": 9.0, "targetLowPrice": 5.0, "targetMeanPrice": 6.95, "targetMedianPrice": 7.0, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 123980000, "totalCashPerShare": 0.663, "ebitda": -77780000, "totalDebt": 61383000, "quickRatio": 3.209, "currentRatio": 3.38, "totalRevenue": 14156000, "debtToEquity": 113.991, "revenuePerShare": 0.09, "returnOnAssets": -0.38858002, "returnOnEquity": -6.06694, "freeCashflow": -57143752, "operatingCashflow": -72631000, "revenueGrowth": -0.275, "grossMargins": 1.0, "operatingMargins": -7.13281, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]